Service Eliminates Over-Packaging by Providing Deep Knowledge of a Product’s Stability Barrier Needs Before It Is Packaged....
Leading to a “Just Right” Solution for Oral Dose Products in Six Weeks
Delaware City, DE – Bilcare Research Inc., one of the world’s largest manufacturers of blister packaging solutions, has launched BilcareOptima™, the pharmaceutical industry‘s most scientifically thorough method to determine ideal packaging solutions for oral dose products.
BilcareOptima™ is an advanced forced drug degradation analysis that determines a product’s susceptibility to various environmental factors, most prevalently humidity, temperature and light, to recommend the perfect packaging solution for products before they are ever packaged. In doing so, the service provides a level of insight into packaging-based product stability never before available in the United States.
Highly sophisticated, BilcareOptima™ offers a foresight-oriented upgrade from traditional drug stability testing, which is generally performed in hindsight after a product is packaged. Today’s habit of “inspection after the fact” is a trial-and-error process that routinely leads to over-packaging to compensate for incomplete understanding of a product’s stability risks and therefore barrier requirements under differing climatic conditions. BilcareOptima™ eliminates this back-and-forth process that, in the pharmaceutical industry, can often mean the difference between a successful product launch and a costly delay.
Reduced costs through enhanced knowledge: BilcareOptima’s benefits
BilcareOptima™ avoids over-packaging by determining the exact barrier a product’s packaging must provide in order for a drug to remain stable, safe and effective upon use. To achieve this, products are studied under various environmental conditions to determine a complete portfolio of its characteristics. These include:
- Physical degradation
- Hygroscopicity
- Chemical degradation
- Drug release properties
- Hardness and friability
- Photo sensitivity
- Gas liberation
- Material-product interaction
And just to be on the safe side, the process is performed in triplicate: three separate batches are subjected to BilcareOptima's all-encompassing tests, resulting in a packaging solution recommendation that is exactingly accurate.
Efficient efficacy: Speed to market through BilcareOptima™
BilcareOptima™ is as expedient as it is thorough. Recommendations on a product’s ideal packaging are made within six weeks and, for post-analysis proof, Bilcare Research provides complete documentation that the product's packaging was scientifically developed based on its stability factors.
For more information on BilcareOptima™, visit www.BilcareOptima.com
About Bilcare Research Inc.
Bilcare Research Inc. is an innovation-led solutions provider that partners with the global pharmaceutical and healthcare industry to improve patient healthcare outcomes. The company is one of the world’s leading manufacturers of pharmaceutical and medical blister films and foils, supplying a full range of thermoforming films, Alu-lid foils, and cold form foils. In doing so, Bilcare Research delivers effective, affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands from counterfeiting.
Bilcare Research’s three defined business areas – Pharmaceutical Packaging Innovations, Global Clinical Supplies and Bilcare Technologies for brand authentication and security – combine to address the industry’s five C’s: counterfeiting, compliance, communication, convenience and cost.
Bilcare Research has a global footprint with modern manufacturing and R&D plants located across U.S., Europe, India and Singapore. The company employs more than 2,000 people. Visit www.bilcaresolutions.com or call (302) 416-0974.